Shanghai Henlius Biotech's (HKG:2696) new drug application for a new indication of HANSIZHUANG in combination with pemetrexed and carboplatin has been approved by China's National Medical Products Administration, a Tuesday bourse filing said.
The new indication of the drug in combination with pemetrexed and carboplatin is for the first-line treatment of patients with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments